Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Licence agreement secured in Republic of Korea for Accrufer®

7 Oct 2021

Shield Therapeutics plc, announces that it has entered into an exclusive licence agreement for Accrufer® with KOREA PHARMA CO.,LTD (“Korea Pharma”) in the Republic of Korea (“South Korea” or “Korea”).  Alongside the financial terms of the licence, Korea Pharma will undertake and pay for all activities to achieve marketing authorisation and then commercialise Accrufer® in Korea. For further details click here.

Back to news